Added to YB: 2026-06-09
Pitch date: 2026-06-07
KYMR [bullish]
Kymera Therapeutics, Inc.
-1.04%
current return
Author Info
No bio for this author
Company Info
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
Market Cap
$6.1B
Pitch Price
$74.73
Price Target
120.72 (+62%)
Dividend
N/A
EV/EBITDA
-13.92
P/E
-20.91
EV/Sales
89.99
Sector
Biotechnology
Category
growth
Kymera Therapeutics, Inc. - $KYMR
KYMR: Pure-play protein degradation biotech; KT-621 oral STAT6 degrader could rival Dupixent ($13B+ injectable) as a pill. Phase 1b: 98% degradation, clean safety, Fast Track. Top BVF/Baker/Avoro holding (Perceptive exited). $6.1B cap, $651M cash, 1.8yr runway. Catalysts: Q3'26 LTE data, Q1'27 BROADEN2 interim (key), mid/late-'27 topline. 18 analysts 100% bullish, avg PT $120.72 (62.8% upside). ~30-40% Phase 2b fail risk.
Read full article (4 min)